MK-677 Growth Hormone Secretagogue Fails to Slow Alzheimer's Progression in Trial
Background
Alzheimer's Disease (AD) is a devastating and progressive neurodegenerative condition characterized by cognitive decline, for which effective treatments remain elusive. Growth hormone (GH) has been hypothesized to possess neuroprotective properties, and MK-677 (ibutamoren) is a growth hormone secretagogue known to stimulate the body's natural release of GH. Previous preclinical and early clinical observations hinted at potential cognitive benefits, but the clinical efficacy of MK-677 in slowing AD progression in a robust trial remained unconfirmed.
Results
After 12 months of continuous treatment, the study found no statistically significant difference in the primary cognitive endpoints between the MK-677 treatment group and the placebo group. The mean change in ADAS-Cog score, which measures cognitive impairment, was +7.2 points for patients receiving MK-677 and +6.8 points for those on placebo (p=0.45), indicating similar rates of cognitive decline in both groups. Similarly, the CDR-SB, a measure of functional impairment, showed a mean change of +2.1 points for the MK-677 group and +2.0 points for the placebo group (p=0.78). > The study definitively concluded that MK-677 did not demonstrate any clinical benefit in slowing the progression of Alzheimer's Disease over the 12-month treatment period. Secondary endpoints, including assessments of daily living activities and global clinical change, also revealed no significant differences between the treatment arms.
Why It Matters
This study provides crucial and definitive evidence that MK-677, despite its ability to elevate growth hormone levels, does not offer a viable therapeutic strategy for slowing the progression of Alzheimer's Disease. This finding is important for guiding future research, as it helps to redirect efforts away from growth hormone secretagogues as a primary intervention for AD. It underscores the complexity of neurodegenerative diseases and the need for more targeted approaches, potentially focusing on other mechanisms of action or earlier disease stages.